Boston-based Vertex Pharmaceuticals failed to reach its clinical goals for its type 1 diabetes treatment, VX-264, leading to the discontinuation of the program. The effort focused on replacing lost insulin production with islet cells derived from donor stem cells, avoiding the typical need for chronic immunosuppression in cell therapy. However, the failure doesn’t rule out the use of the therapy’s cells (zimislecel) in another form, which is currently in Phase 3 testing.
Hackers are selling counterfeit phones with crypto-stealing malware
Kaspersky has identified thousands of low-cost Android smartphones sold online that come with preinstalled malware programmed to steal cryptocurrency details. The devices are infected with
